Skip to main content

AgeX Therapeutics, Inc. (AGE)

0.905 0.002 (0.21%)
Oct 25, 2021 4:00 PM EDT - Market closed

Company Description

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States.

The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as the ischemic heart.

Its lead drug-based therapeutic candidate in discovery is AGEX-iTR1547, a drug-based formulation to restore regenerative potential in a range of aged tissues afflicted with degenerative diseases.

In addition, the company markets human embryonic stem cells; and GeneCards Database Suite, including genomic interpretation algorithms and analysis tools for use by researchers at pharmaceutical and biotechnology companies, and other institutions.

AgeX Therapeutics, Inc. has a research collaboration with the University of California, Irvine on neural stem cell research program for Huntington's disease and other neurological disorders; a collaboration with Sernova Corp.; and a research collaboration with The Ohio State University using AgeX's brown adipocyte tissue cell therapy candidate AgeX-BAT1 in mice to determine whether transplantation of AgeX-BAT1 cells may improve diet-induced obesity, metabolic health, and cardiac function.

The company was founded in 2017 and is based in Alameda, California.

AgeX Therapeutics, Inc.
AgeX Therapeutics Logo
CountryUnited States
IPO DateNov 29, 2018
SectorHealth Care
CEOMichael West

Contact Details

965 Atlantic Ave Ste 101
Alameda, California 94501-1079
United States
Phone510 671 8370

Stock Details

Ticker SymbolAGE
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
CIK Code0001708599
CUSIP Number00848H108
ISIN NumberUS00848H1086
Employer ID82-1436829

Key Executives

Dr. Michael D. WestFounder, President, Chief Executive Officer and Director
Eun-Jae Park CPAChief Financial Officer
Dr. Nafees Naseer Malik M.D.Chief Operating Officer
Dr. Ivan LabatChief Information Officer
Judith SegallSecretary